Open AccessAnti cytokine therapy of secondarily-progressing multiple sclerosis (ms)
Author(s) -
Eugene Gusev,
Т. L. Demina,
А. Н. Бойко,
А. V. Buglak,
I. А. Belyaeva,
N F Smirnova,
Т. G. Alekseeva,
М В Пащенков,
В. Skurkovich,
Déirdre Kelly,
S. V. Skurkovic
Publication year - 1997
Publication title -
nevrologičeskij vestnik
Language(s) - English
Resource type - Journals
eISSN - 2304-3067
pISSN - 1027-4898
DOI - 10.17816/nb79894
Subject(s) - multiple sclerosis , cytokine , antibody , medicine , clinical trial , immunology , tumor necrosis factor alpha
For treating active forms of secondarily-progressing multiple sclerosis a preliminary clinical trial was performed by two courses: antibody-to-cytokine course (INT, INT and TNF) and cyclosporin А-course (sandimmun). Data of preliminary test of antibodies to cytokines evidence to possibility of performing further clinical trials "antibodies to INT and to TNF (to a lesser degree)" during active forms of progressive MS. Were obtained the results, evidencing to a possible use of sandimmun in constantly progressive forms of secondarily progressing disease, when favourable clinical effect coincided with supression of cytokine IL-2 production and lowering of activeness of immunocytes.